Make a Difference in Accelerating Your Checkpoint & Combination Immunotherapy Programs

[unex_ce_button id="content_1khp77dvb,column_content_rcfcgn7j5" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="full_width" button_alignment="center" button_text_spacing="1px" button_bg_color="#0fa8db" button_padding="15px 20px 15px 20px" button_border_width="0px" button_border_color="#0fa8db" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#87c6db" button_border_hover_color="#87c6db" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar >[/ce_button]

IsoPlexis is empowering the ability to combine immunotherapies from discovery through the entire translational process

By finding the small groups of potent immune cells that are driving response, IsoPlexis is working with leaders to address challenges across solid tumor indications in oncology, related to understanding potency, durability and toxicities earlier in the development process.

Complex therapy interactions:

 

Influencing each part of the cancer
immunity cycle:

  • T cells and various subtypes Data >
  • NK cells Data >
  • Myeloid cells (e.g., macrophages, monocytes) Data >

Literature:
Checkpoint & Combination Immunotherapy

Join us to learn more about how we are accelerating immunotherapy programs across the discover-optimize-predict continuum with our unique cellular analysis metrics

[unex_ce_button id="content_jc8vbslgl,column_content_6k1nhbixn" button_text_color="#00b1d8" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="left" button_text_spacing="1px" button_bg_color="#efefef" button_padding="10px 20px 10px 20px" button_border_width="0px" button_border_color="#efefef" button_border_radius="0px" button_text_hover_color="#00b1d8" button_text_spacing_hover="1px" button_bg_hover_color="#d6d6d6" button_border_hover_color="#d6d6d6" button_link="https://isoplexis.com/wp-content/uploads/2019/02/IsoPlexis-AppHighlight-Bispecifics.pdf" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application highlight >[/ce_button]

Follow our correlative data across immunotherapy development, in multiple cell types and indications

[unex_ce_button id="content_nu8khu7py,column_content_558u0089c" button_text_color="#ffffff" button_font="bold" button_font_size="16px" button_width="auto" button_alignment="center" button_text_spacing="1px" button_bg_color="#ff6d1d" button_padding="10px 48px 10px 48px" button_border_width="0px" button_border_color="#ff6d1d" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#ff6d1d" button_border_hover_color="#ff6d1d" button_link="" button_link_type="url" button_link_target="_self" has_container="" in_column="1"]ENABLING DISCOVERY[/ce_button]

IsoPlexis' systems are revealing choice in novel bispecific development targeting the tumor microenvironment

[unex_ce_button id="content_nu8khu7py,column_content_iujebq31d" button_text_color="#ff5c05" button_font="bold" button_font_size="14px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#ededed" button_padding="10px 15px 10px 15px" button_border_width="0px" button_border_color="#efefef" button_border_radius="0px" button_text_hover_color="#ff6d1d" button_text_spacing_hover="1px" button_bg_hover_color="#d6d6d6" button_border_hover_color="#d6d6d6" button_link="https://www.isoplexis.com/discover-combination-therapy" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Follow our data >[/ce_button]
[unex_ce_button id="content_nu8khu7py,column_content_xdjj0vpoy" button_text_color="#ffffff" button_font="bold" button_font_size="16px" button_width="auto" button_alignment="center" button_text_spacing="1px" button_bg_color="#0fa8db" button_padding="10px 30px 10px 30px" button_border_width="0px" button_border_color="#0fa8db" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#0fa8db" button_border_hover_color="#0fa8db" button_link="" button_link_type="url" button_link_target="_self" has_container="" in_column="1"]OPTIMIZING LEAD CHOICE[/ce_button]

IsoPlexis' PSITM helps uncover the T cell mechanism of agonists used in combination with reengineered cell therapies

[unex_ce_button id="content_nu8khu7py,column_content_0su52fzur" button_text_color="#34bad8" button_font="bold" button_font_size="14px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#efefef" button_padding="10px 15px 10px 15px" button_border_width="0px" button_border_color="#efefef" button_border_radius="0px" button_text_hover_color="#34bad8" button_text_spacing_hover="1px" button_bg_hover_color="#d6d6d6" button_border_hover_color="#d6d6d6" button_link="https://www.isoplexis.com/optimize-combination-therapy" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Follow our data >[/ce_button]
[unex_ce_button id="content_nu8khu7py,column_content_xtfr9xyp8" button_text_color="#ffffff" button_font="bold" button_font_size="16px" button_width="auto" button_alignment="center" button_text_spacing="1px" button_bg_color="#4e8200" button_padding="10px 43px 10px 43px" button_border_width="0px" button_border_color="#4e8200" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#4e8200" button_border_hover_color="#4e8200" button_link="" button_link_type="url" button_link_target="_self" has_container="" in_column="1"]PREDICTING RESPONSE[/ce_button]

Our systems  are able to uniquely stratify patient response in solid tumor based on TIL polyfunction

[unex_ce_button id="content_nu8khu7py,column_content_sdxbifvxt" button_text_color="#4e8200" button_font="bold" button_font_size="14px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#efefef" button_padding="10px 15px 10px 15px" button_border_width="0px" button_border_color="#efefef" button_border_radius="0px" button_text_hover_color="#4e8200" button_text_spacing_hover="1px" button_bg_hover_color="#d6d6d6" button_border_hover_color="#d6d6d6" button_link="https://www.isoplexis.com/predict-combination-therapy" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Follow our data >[/ce_button]

Publications & Presentations
Checkpoint & Combination Immunotherapy

[unex_ce_button id="content_jx3qunf6n,column_content_rybl4703m" button_text_color="#ff5900" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="center" button_text_spacing="1px" button_bg_color="#efefef" button_padding="10px 20px 10px 20px" button_border_width="0px" button_border_color="#efefef" button_border_radius="0px" button_text_hover_color="#ff5900" button_text_spacing_hover="1px" button_bg_hover_color="#d6d6d6" button_border_hover_color="#d6d6d6" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Contact us for a seminar
on our datasets >[/ce_button]

Single-cell proteomic analysis of T cells stimulated by Bi-specific T cell Engagers shows a robust and unique polyfunctional secretion profile. Mackay S, Paczkowski P, Flynn B, Morse K, Liu D, Coupet TA, Godbersen C, Sentman CL, Zhou J. Presented at SITC Annual Meeting 2018.

Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 induces a clinical response and a T cell response locally and systemically. Seo YD, Zhou J, Morse K, Patino J, Mackay S, Kim EY, Conrad III EU, O'Malley RB, Cranmer L, Lu H, Hsu FJ, Xu Y, Loggers E, Hain T, Pillarisetty VG, Kane G, Riddell S, Meulen J, Jones RL, Pollack SM. Journal of Clinical Oncology, 36, Suppl 5S (2018).

Enhanced Expansion and Tumor Targeting of Adoptively Transferred T Cells with NKTR-214. Parisi G, Saco J, Salazar F, Krystofinski P, Tsoi J, Zhang R, Puig Saus C, Zhou J, Hu-Lieskovan S, Comin-Anduix B, Wu A, Charych DH, Ribas A. Session PO.CL06.03 - Adoptive Cell Therapy 3. American Association for Cancer Research Annual Meeting 2018.

Enhanced TLR2 Responses in Multiple Sclerosis. Fujiwara M, Anstadt EJ, Flynn B, Morse K, Ng C, Paczkowski P, Zhou J, Mackay S, Wasko N, Nichols F, Clark RB. Clinical and Experimental Immunology (2018).

Single-cell PSI of CD8+ TILs in melanoma shows uniquely sensitive correlates with response to anti-PD-1/CTLA4 therapy, where histology and serum cytokines were unable to detect significant associations. Mackay S, Flynn B, Morse K, Paczkowski P, Chen J, Liu D, Bacchiocchi A, Heath JR, Fan R, Sznol M, Halaban R, Zhou J. Presented at SITC Annual Meeting 2018.

Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Heath JR, Fan R, Halaban R, and Zhou J. Presented at TRCCC Annual Meeting 2018.

Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Fan R, Halaban R, and Zhou J. Journal of Clinical Oncology, 35 (9), Suppl. 7S (2017).